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Abstract
Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly
virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral
Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in
Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named
myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on
European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of
inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American
S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in
human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of
certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to
treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent
ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an
oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of
MYXV in rabbits as well as its potential in human medicine in the twenty-first century.
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1. The virus
Myxoma virus (MYXV) is a member of the genus Lepori-
poxvirus, subfamily Chordopoxvirinae, belonging to the
family of Poxviridae. MYXV contains a large linear double
stranded deoxyribonucleic acid (DNA) genome consisting
of 159 unique viral genes, with diploid terminal inverted
repeats (TIRs). Each TIR contains twelve viral genes, nine
of which encoding diverse immunomodulating proteins,
giving a total of 171 genes [1]. The viral genome is encap-
sidated within a brick shaped virion, and the complete
replication cycle of MYXV takes place exclusively in the
cytoplasm of the infected cells from where it expresses a
spectrum of host-interactive immunomodulatory proteins
[2]. The virus infects only rabbits and European Brown
Hares (only occasionally with clinical signs) in the wild,
and is nonpathogenic in any tested hosts apart from lago-
morphs, but MYXV can replicate in cultured cells from
many species, including most human cancer cells which
are particularly permissive for MYXV [3,4].
2. History
The disease caused by MYXV was seen for the first time
in laboratory rabbits in 1896 by Giuseppe Sanarelli in
Montevideo, Uruguay [4] Sanarelli was invited by the
Uruguayan government to found a new Institute of
Hygiene in Montevideo that required the production of
antibodies, for which European rabbits were necessary.
Following their importation from Europe, these rabbits
were housed in an outdoor facility that was open to bit-
ing arthropod vectors, such as mosquitoes. Shortly
thereafter, the European rabbits were struck down by a
highly contagious and lethal disease, which was charac-
terized by multiple lesions and tumors of the skin and
conjunctiva. Sanarelli named this new rabbit disease
myxomatosis and thought it might be caused by an
infectious agent, which was confirmed later on by isola-
tion of the causative poxvirus, called MYXV [4].
The European rabbit evolved in Europe and Eastern
Asia, and prior to human intervention was not found in
the rest of the world, including Australasia and the
Americas. During the colonization of new territories, the
European rabbit was often taken along as a source of
meat or for sport hunting, and this is what occurred
during the colonization of Australia in 1860. Between
1860 and 1930, a growing population of feral European
rabbits derived from a small number of initial breeding
pairs spread over the entire continent and their numbers
rose up to an estimated three billion [5]. Since it was
estimated that ten rabbits consumed as much vegetation
as a single domesticated sheep, the elimination of
rabbits was seen as a very necessary step to economic-
ally raise the food and wool production of Australia.
Rewards were issued to attract new proposals for redu-
cing the size of the feral rabbit population and one of
the people who responded was Louis Pasteur, who
recommended using Pasteurella cultures that are patho-
genic to rabbits. But due to the well-justified skepticism
of the Australian government, he was not allowed to
release this microbial agent into the wild [4,6].
Since the original MYXV had a mortality rate of 99.5%
in the European rabbit, it was first suggested as a possi-
ble means of controlling the Australian feral rabbit
population in 1936. Shortly thereafter, the Australian
government approved several field release experiments
[4,5]. Before the Second World War, two such field tests
were conducted, the first of which took place on an
island off the South Australian coast and the second in
the dry inland outback region. Both experiments showed
almost no prolonged spread of the test virus. After the
Second World War, MYXV was again tested in a third
region in Southern Australia with more seasonal rainfall
[6]. Since it was originally thought that MYXV was
mostly spread rabbit-to-rabbit by direct contact, the
field-tests were conducted mostly in the dry interior of
Australia during autumn, winter and spring but without
much success in inducing widespread disease in the rab-
bit population [5]. However, shortly after these field
tests when the rainy season ensued, numerous dead
MYXV-infected rabbits were found alongside rivers and
streams, infected via the seasonally expanded popula-
tions of Culex annulirostris, a mechanical vector for
MYXV. However, it rapidly became clear that almost
any biting or sucking arthropod could serve as a vector
for the virus, which enabled MYXV to spread over large
areas [5,6]. An estimated 400 million rabbits succumbed
in as little as one year, and within less than a decade,
the feral rabbit population was reduced by 95% [4,6]. In
contrast to South America where the virus co-existed
with Sylvilagus sp. hosts in a relatively nonpathogenic
relationship, there was no natural host reservoir species
for MYXV present in Australia. Therefore, MYXV was
constrained to sustain itself in the same host animals
that it was killing with such extreme efficiency. This led
to a strong selection for less virulent MYXV strains that
killed their European rabbit hosts with less efficiency
than the originally introduced high pathogenicity strain
of MYXV, enabling more extensive replication and
spread of the virus by increasing the survival time of its
host [4]. At the same time, the selection pressure
exerted by this extremely virulent pathogen caused the
host rabbit population to select for the genetically resis-
tant strains that were less susceptible to the lethal dis-
ease manifestations of myxomatosis. The co-
evolutionary selection pressure reduced the overall
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mortality rate of MYXV in the field rabbits to less than
30% within seven years after introducing MYXV in Aus-
tralia. After the introduction of MYXV in Great Britain
and France, a similar course of co-evolution between
MYXV and its rabbit host was seen [7-9] and at present,
MYXV is sustained as a chronic enzootic in rabbit
populations in America, Southern Europe, New Zealand
and Australia [10] (Figure 1).
3. Pathogenesis and disease symptoms
The pathogenesis in immunologically naïve European
rabbits after infection with MYXV largely depends on
the MYXV strain and the rabbit breed or strain. Aside
from naturally occurring MYXV strains, frequently used
strains in laboratories are the standard laboratory strain
(SLS), the Lausanne strain and the Uriarra (Ur) strain.
The SLS and the Lausanne strain, which are both viru-
lent MYXV strains originally isolated in South America,
were released in Australia and Europe, respectively
[4,7,11]. The Ur strain was isolated from more resistant
field rabbits in Australia in 1953, three years after the
first release of SLS. Since the Ur strain had already
undergone three years of selection to less virulence, it is
often used as a model for attenuated MYXV strains
[12]. In this review, the pathogenesis of an SLS infection
in laboratory rabbits will be described extensively as the
canonical example of myxomatosis, whereas the other
pathogenesis patterns will be discussed briefly in com-
parison to this standard model.
Laboratory rabbits can be infected with MYXV
through direct contact with an infected individual, by an
arthropod vector, or simply in the laboratory by direct
needle inoculation (Figure 2). Through the infection of
dendritic cells (DCs) at the primary infection site, and
subsequent circulation via the lymphatic and vascular
system, MYXV then spreads throughout the body into
numerous secondary organs. New myxoma lesions
("myxomes”) are formed at multiple secondary sites on
the skin where arthropod vectors can acquire high
enough titers on their biting organs in order to success-
fully infect new hosts once they have been serially bitten
by the vector (Figure 2) [2,12,13].
This course of disease induces a number of diagnostic
clinical symptoms that have been well documented for
both the SLS and the Lausanne strains in laboratory
rabbits, which are representative for the rabbit popula-
tion used in either the meat industry or as pets. Essen-
tially all infected immunologically naive laboratory
rabbits will develop clinical myxomatosis characterized
by a pink color and edema at the point of inoculation,
followed by progressive conjunctivitis and serous/muco-
purulent secretion from eyes and nose [7,11]. In addi-
tion, the infection is accompanied by swelling of the
anogenital region and supervening bacterial infections in
the respiratory tract as the immune system of the
infected host progressively collapses. Animals will
usually die 10-14 days post infection (dpi) [14]. Wild
Australian rabbits from more resistant populations
infected with the SLS strain or laboratory rabbits
infected with the Ur strain will display a similar disease
course, however usually with a reduced degree of sever-
ity, including a delayed onset of clinical symptoms, and
a lower overall mortality (Table 1).
Apart from the classical nodular form of myxomatosis
discussed above, a second less frequent form of myxo-
matosis exists. This atypical myxomatosis is believed to
spread by direct contact, rather then by biting arthro-
pods [15]. The clinical signs of this second form, named
amyxomatous myxomatosis, are predominantly respira-
tory while skin lesions are few and small [16].
Figure 1 MYXV worldwide distribution. The global distribution of MYXV during the period 01/07/2009-31/12/2009 (copied from [152).
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4. Immunomodulatory proteins of MYXV
The reason for the successful replication of MYXV in
rabbits is due to the fact that MYXV encodes a vast
array of immunomodulatory proteins (Table 2), some of
which are rabbit-specific and others are capable of
recognizing immune targets from other hosts, including
mice or humans. The gene sequences of these proteins
are preferentially located at or near the genomic regions
closest to the TIRs of the genome [17] and for many of
these proteins, their function has already been investi-
gated in vitro and/or in vivo. For other MYXV proteins,
however, their functions are solely predicted by
Figure 2 The pathogenesis of nodular myxomatosis. At the site of inoculation (A) viral replication occurs first in the peripheral epidermal
cells and then in cells deeper in the dermis (B). This initially induces only a mild primary inflammation and mainly attracts neutrophils at early
times. Resident Major Histocompatibility Complex-2 (MHC-2) positive cells, such as Langerhans cells, are also infected (C) [2,12,13]. When these
cells migrate to the draining lymph node to present viral epitopes in the T-cell zone, they also traffic live virus and T-lymphocytes become
infected with MYXV as well (D). This results in wide spread cell death in the T-cell zone of many lymphoid organs and also enables MYXV to
spread in a cell-associated manner when these infected T-lymphocytes migrate through the blood and reticuloendothelial circulation. Once in
the blood and lymph, MYXV spreads via infected leukocytes to different organs such as the liver, spleen, other distant lymph nodes, testis and
epidermis (E). The MYXV replication in these organs induces a strong polymorphonuclear (PMN) cell-influx and in the skin secondary lesions are
formed that contain high viral titers, favoring successful spread by mechanical vectors (F) [2,12].
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comparing them to analogous related genes from eukar-
yotic cells or other viruses, such as the vaccinia virus
(VACV) [18]. In the present review, the functions of
these immunomodulatory proteins will be only briefly
discussed but for a more elaborate description of the
most important examples, we would like to refer to
other recent reviews [19-22]. Moreover, aside from this
variety of immunomodulatory proteins, MYXV also
encodes genes with important functions in disease
pathogenenis, e.g. M127L encodes the DNA repair
enzyme photolyase which can promote MYXV survival
in the environment [23]. As a description of these pro-
teins is beyond the scope of this review, we would also
like to refer for these proteins to other reviews [1,23,24].
4.1. MYXV proteins with anti-apoptotic functions
4.1.1. Inhibition of pro-apoptotic molecules
Multicellular organisms use programmed cell death, also
designated apoptosis, as an innate defense mechanism
to eliminate cells that pose a threat for the rest of the
organism, such as virus-infected cells [25,26]. Since
apoptosis can have a negative effect on viral replication
Table 1 Comparison of symptoms in wild and domestic rabbits infected with different MYXV strains inducing nodular
myxomatosis (adapted from [7,11])
Day
pi
Laboratory rabbits Wild rabbits
SLS Lausanne Uriarra (Ur) SLS Uriarra (Ur)
1
2 Pink & edematous
inoculation site
Pink/edematous inoculation site Pink inoculation site
3 Pink/edematous
inoculation site
4 Conjunctivitis Conjunctivitis Pink
inoculation
site
5 Secondary skin lesions
Anogenital edema
Conjunctivitis
Anogenital edema
6 Secondary skin lesions &
anogenital edema
Serous eye discharge Conjunctivitis &
Anogenital edema
7 Respiratory distress Mucopurulent eye discharge & purple/
black inoculation site
Mild
conjunctivitis
8 Necrotic inoculation site; Edematous
eyelids; Respiratory distress
Secondary skin lesions
9 Secondary skin
lesions
10 Severe respiratory distress
Secondary lesions across
the skin #
Serous secretion from inoculation site Respiratory distress Respiratory distress Mild
anogenital
edema;
Secondary skin
lesions
11 Severe dyspnoea; Secondary lesions
across the skin #
12 Lesion regression
13
Day
pi
Laboratory rabbits Wild rabbits
14
15 Improved breathing;
Decreased anogenital edema
Lesion
regression
16
17 Lesion regression
18
19
20 Still recovering Virtually recovered
#: euthanasia of the experimentally infected animals due to too severe clinical symptoms; pi: post inoculation
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and spread, many viruses, including MYXV, have devel-
oped multiple strategies to inhibit this process. One
point of interference is the direct inhibition of key pro-
apoptotic molecules.
The MYXV protein M-T2 (M002R/L) is a secreted
tumor necrosis factor receptor (TNFR) homolog that
inhibits apoptosis by binding and subsequently inhibit-
ing rabbit TNF via a conserved ligand-binding domain
at the N-terminus of the viral protein [27-29]. A highly
conserved viral preligand assembly domain (vPLAD) on
the M-T2 protein is responsible for inhibiting intracellu-
lar apoptosis, making it the first described viral immu-
nomodulatory protein for which two separate domains
with distinct immune inhibiting functions are known
[29,30].
M11L is a viral protein that localizes to the outer
mitochondrial membrane through close association with
the mitochondrial peripheral benzodiazepine receptor
(PBR) component of the permeabilitytransition (PT)
pore. There, M11L prevents the release of mitochondrial
cytochrome c induced by staurosporine or protopor-
phyrin IX (PPIX), which are ligands of PBR [31,32].
Furthermore, M11L is also able to inhibit apoptosis by
binding with B-cell lymphoma 2 (BCL2)-antagonist/
killer (Bak), which, following pro-apoptotic stimuli, is
also able to release cytochrome c and subsequently
induce cell death [26,33,34]. Another function for M11L
is the ability to interact with activated Bcl-2 associated
× protein (Bax), which it inhibits when it is translocated
from the cytoplasm to the outer mitochondrial mem-
brane during viral infection [35].
Although not yet demonstrated experimentally,
M146R is also a potential inhibitor of the pro-apoptotic
Bcl-2 family, in the sense that the MYXV protein is clo-
sely related to the VACV protein N1L, which has been
shown to bind and inhibit Bcl-2 proteins [36,37].
Recently, it was shown that N1L also retains a role in
influencing the Toll-like receptor (TLR) signaling path-
way [38]. Also, and even more recently, it was found
that the VACV ortholog N1L of ectromelia virus
Table 2 Immunomodulatory proteins of MYXV
ORF Protein name Function references
M002R/L M-T2 TNFR homolog; inhibits TNF/TNFR; prevents apoptosis of lymphocytes intracellularly [27-30]
M11L Binds with Bak and/or Bax; inhibits apoptosis [33,34]
M146R Postulated to bind Bcl-2 proteins and inhibit TLR-mediated innate responses [1,38]
M005R/L M-T5 Enhances degradation of CDK inhibitors; prevents checkpoint-induced apoptosis [42-44]
M150R MNF ANK-repeat protein; inhibits NF-B [45,48]
M148R ANK-repeat virulence factor, but no specific function defined to date [49]
M149R ANK-repeat virulence factor, but no specific function defined to date [49]
M153R MV-LAP Downregulates cell surface CD4, Fas-CD95 and MHC-1 [13,50,51]
M143 Ubiquitin ligase with a possible anti-apoptotic function [1]
M004R/L M-T4 Possible interference with BAP31 in the ER; apoptosis inhibitor [13,52,53]
M156R PKR pseudosubstrate and inhibitor [19,57]
M029L Predicted inhibitor of PKR via dsRNA binding [1]
M062R Host range factor essential for replication in rabbit or human cancer cells; binds SAMD9 [1,61,65]
M063R Host range factor, essential for replication in rabbit cells [1,61,62]
M064R Related to M062 and M064 host range factors but function not yet determined [1,61]
M001R/L M-T1 CC-chemokine binding protein [66,67,153,154]
M104L Postulated inhibitor of chemokine receptor signaling [1]
M007R/L M-T7 Secreted inhibitor of IFN-g and chemokines; anti-inflammatory activities [69]
M008R/L Serp-1 Secreted serpin that inhibits diverse host serine proteases; anti-inflammatory activities [70,155-157]
M151R Serp-2 Intracellular serpin that inhibits ICE and granzyme B [71,73,158]
M152R Serp-3 Serpin and virulence factor, but no specific host target yet described [74]
M141R vCD200 Cell surface virulence factor that inhibits CD200R+ leukocytes (also called vOX-2) [1,76]
M121R/M122R Predicted NK regulatory receptor homologs [1]
M128L vCD47 Cell surface virulence factor and CD47 homolog [1,80]
M13L Pyrin-containing protein that inhibits the inflammasomes and NF-B signaling [81,83]
M129R Predicted HIV gp120 homolog, but function still unknown [60]
M130R Predicted HIV Tat homolog; virulence factor [60,86]
M010L MGF Secreted virulence factor, related to TGFalpha and EGF [89]
M135R B19R (VACV) homolog, virulence factor, but no specific function or ligand known [60,90]
M144R C3L/B5R (VACV) homolog, no confirmed function yet [60]
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(ECTV), the causative agent of mousepox, interferes
with host T cell function in vivo, independently of TLR
signaling. This was also illustrated by the impairment of
in vivo ECTV spread when N1L was deleted [39]. This
study provided different results for the virulence factor
N1L than those previously predicted in vitro, emphasiz-
ing again the importance of studying virulence factors in
a natural virus-host system in vivo.
4.1.2. Inhibition by protein-protein interactions by ankyrin
repeat viral proteins
Several MYXV proteins contain ankyrin (ANK) repeats
and a “Pox protein Repeats of Ankyrin C-terminal”
(PRANC) domain (an F-box-like domain), which enable
the binding with unique cellular protein targets [40,41].
Through these protein-protein interactions MYXV
ANK-repeat proteins act as substrate adaptors that can
recruit cellular proteins for ubiquitination and degrada-
tion via the 26S proteasome. This is the case for M-T5
(M005R/L), which binds via an adaptor protein called
Skp1 with the cellular protein cullin-1 in vitro [42]. Cul-
lin-1 is an E3 ubiquitin ligase, which normally binds to
cyclin-dependent kinase (CDK) inhibitors, enzymes that
are otherwise degraded in a cell cycle fashion by protea-
somes. The binding of M-T5 with Skp1/cullin-1 aug-
ments the proteosomal degradation of CDK inhibitors,
like p27-Kip, thereby stimulating the progression of the
cell cycle past the G0/G1 checkpoint that could other-
wise trigger an apoptosis response when the cell cycle
stalls at this checkpoint [42,43]. In vivo experiments
have shown that M-T5 is necessary for MYXV to spread
secondary immune organs in the infected rabbit host
[44], suggesting that M-T5 permits virus spread via
infected lymphocytes that traffic to multiple distal
immune organs [20].
The myxoma nuclear factor (MNF) M150R is crucial
for productive viral infection in vivo and is predicted to
interfere with apoptosis by inhibiting Nucleus Factor-B
(NF-B). This prediction is based on the analogy with
ANK-repeats and the nuclear location of M150R when
compared to cellular NF-B inhibitors (IBs) [45]. NF-
B is an important transcription factor that is activated
by pro-inflammatory stimuli, subsequently translocating
from the cytoplasm to the nucleus where it upregulates
host genes critical for immunity, inflammation and
apoptosis [46]. IBs inhibit NF-B by interfering with
the translocation of the active transcription factor dimer
to the nucleus and hence, a similar action is predicted
for M150R [45,47]. More recently, an alternate possibi-
lity of inhibition has been proposed, where M150R
directs the ubiquitin ligase complex to new substrate
targets, such as NF-B, for ubiquitination and subse-
quently degradation [48]. Both M148R and M149R are
also members of the MYXV ANK-repeat family and
although the virulence of infection with M148R and
M149R deletion mutants was reduced in in vivo experi-
ments, no specific function has yet been determined for
these proteins to date [49].
4.1.3. Inhibition of apoptosis by enhancing the degradation
of cellular proteins
Apoptosis can also be inhibited by downregulating
immune-receptors located on the cell surface, thereby
decreasing the chance of recognition by apoptosis-indu-
cing immune cells such as cytotoxic T-lymphocytes [50].
M153R, also known as Myxoma Virus-Leukemia-Asso-
ciated Protein (MV-LAP), is a ubiquitin ligase which
achieves the downregulation of a number of immune-
receptors at the cell surface, such as major histocompat-
ibility complex 1 (MHC-1), cluster of differentiation
(CD)-4 and Fas (CD95), by augmented endocytosis or by
decreased recycling to the surface [13,50,51]. For Fas, this
downregulation was also accomplished by degradation
[50]. The MYXV protein M143 is also a ubiquitin ligase,
but it remains to be determined whether this viral pro-
tein displays a similar anti-apoptotic role as MV-LAP [1].
M-T4 (M004R/L) is an anti-apoptotic intracellular
virulence factor that has been suggested to function
within the endoplasmic reticulum (ER) of infected cells
where it binds to calreticulin [13,52,53]. Its anti-apopto-
tic action, necessary for in vivo spreading throughout
the infected rabbit host, is still not understood but it
might be explained by a possible interference with the
function of BAP31, an ER-localized host protein
involved in (i) the egress of MHC-1 and other proteins,
(ii) inhibiting apoptosis and (iii) downregulating MHC-1
expression respectively [13,54].
4.1.4. Inhibition of apoptosis by blocking host Protein
Kinase R (PKR)
Protein kinase R (PKR) is upregulated by interferon
(IFN) and is catalytically activated by double stranded
RNA (dsRNA), which can be produced during replica-
tion of many classes of viruses, including poxviruses.
The activation of PKR causes many downstream anti-
viral effects, including apoptosis of the cell, thereby
impeding viral spread, and thus many viruses have
evolved anti-PKR countermeasures [55]. For example,
the VACV K3L protein binds PKR, hereby inhibiting the
phosphorylation of the eukaryotic initiation factor 2
alpha (eIF2a), an important regulator of translation
initiation [56]. Interestingly, the gene sequence of the
protein M156R of MYXV shows extensive sequence
similarities with VACV K3L and a similar function of
M156R was confirmed since M156R protein was shown
to be an efficient substrate for PKR in vitro [57]. Indeed,
MYXV shows a partial resistance against type-1 IFN in
human cells in vitro [58], indicating that MYXV is cap-
able of interfering with IFN signaling in virus-infected
cells, even though it is relatively inhibited when the
anti-viral state is pre-induced prior to virus infection
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[59]. It has been shown that MYXV can partially inhibit
type-1 IFN signaling by blocking the interferon-induced
activation of the Janus kinase Tyk2 in MYXV-infected
human cells. The responsible MYXV protein however, is
yet to be determined [58]. A conserved region of
M029L, located in its C-terminal domain sequence,
shows strong resemblance with the dsRNA binding
region of the VACV gene E3L, which is responsible
decreasing the activation of PKR [1,56,60].
In addition, M062R, M063R and M064R are all ortho-
logs of the VACV host range protein C7L, although only
M062R shows similar host range capabilities as C7L as
determined by gene swap experiments in the context of a
VACV infection [1,61]. M063R shows sequence similarity
with its C-terminal half a with a glutamate-rich domain
of the cellular death-domain associated protein, Daxx,
leading to the hypothesis that M063R can inhibit Fas-
associated cell death through interfering with the func-
tion of Daxx [1,61,62] However, this model remains
unproven and it is still not completely understood under
which circumstances Daxx functions as either a pro-
apoptotic or an anti-apoptotic protein [63,64]. Alterna-
tively, it is hypothesized that M063R functions as a host
range gene like M062R, but that it exerts this function
through a different pathway [62,65]. Recent evidence sug-
gests that M062R, but not C7L, binds to a specific host
anti-viral protein called “sterile alpha motif domain con-
taining protein 9” (SAMD9) implicated in human inflam-
matory disorders, suggesting that even these closely
related viral host range factors may block cellular self-
defense pathways by different mechanisms [65].
4.2. MYXV proteins interfering with leukocyte chemotaxis
The coordinated recruitment of leukocytes at the site of
infection is an important aspect of the early immune
response against viruses [66]. Therefore, it is not sur-
prising that poxviruses such as MYXV have also devel-
oped multiple ways to interfere with this process. M-T1
(M001R/L) is a secreted viral protein that is unnecessary
for productive viral replication but it can bind and inhi-
bit chemokines of the CC-subfamily in vitro, thereby
inhibiting the directional migration and activation of
these cells in vivo [66,67]. In contrast, M-T1 was not
able to bind or inhibit chemokines of the CXC subfam-
ily, at least as assessed by chemical crosslinking in vitro,
such as CXCL8 (ie IL-8, in humans), and this could
explain why neutrophils are the dominant early respon-
der leukocytes at sites of infection in experimentally
MYXV-infected laboratory rabbits [12,67].
M104L is a small hydrophobic MYXV protein which
shares amino acid identity of 42% over a 40-residue
region (containing a receptor domain implicated in che-
mokine receptor signaling) with a subset of the trans-
membrane domains of the IL-8 receptor analogue
ORF74 of Ateline herpesvirus 3, which is believed to
inhibit the signaling of a yet to be determined chemo-
kine receptor via heterodimerization, hereby preventing
the formation of functional receptor dimers [1]. Another
viral MYXV protein, M-T7 (M007R/L), which is an
abundantly secreted 37 kDa glycoprotein from MYXV-
infected cells, binds rabbit interferon-g (IFN-g), hereby
inhibiting interferon-g (IFN-g) through competitive
binding [68]. In addition, it was shown that M-T7 pro-
tein is able to bind chemokines of the CXC, CC and C
subfamilies in vitro in a pan-species specific fashion,
thereby blocking the chemokine-mediated recruiting of
leukocytes from many species, including rabbits, mice
and humans [69].
4.3. MYXV serpins that inhibit cellular pro-inflammatory
or pro-apoptotic proteases
Serine protease inhibitors (serpins) are the largest family
of cellular protease inhibitors and MYXV encodes three
members, each with its own specific functions [1]. Serp-
1 (M008.1R/L) is a secreted MYXV serpin that is able to
bind and inhibit the functions of several human cellular
proteases, such as plasmin, urokinase, plasminogene
activator and C1s of the complement cascade [70].
However, more research is needed to clarify the interac-
tions of Serp-1 with similar cellular proteases in the rab-
bit and the implications of such interactions on the
course of disease. Serp-2 (M151R), on the other hand, is
an intracellular cysteine proteinase that decreases the
secretion of bioactive IL-1b by inhibiting the IL-1b-con-
verting enzyme (ICE) in vitro [71]. Serp-2 is also a weak
inhibitor of granzyme B, which plays an important role
during T cell-induced apoptosis [72,73]. Serp-3 (M152R)
is the third MYXV protein with a canonical predicted
serpin structure, although it has several apparent
domain deletions compared to the gene sequences of
other serpins [74]. When this Serp-3 gene is deleted
from MYXV, no secondary skin lesions are observed in
rabbits in vivo, despite the fact that no decrease in viral
replication nor an increase of apoptosis can be detected
in cultured cells [74].
4.4. MYXV proteins that interfere with leukocyte
activation
MYXV encodes M141R, a structural homologue of
CD200, which is a cellular membrane-bound immune
cell surface protein that is present on a broad range of
cells [1,75]. Cellular CD200 functions as a ligand for a
receptor (CD200R) which is only present on myeloid
cells and is thought to function by transmitting inhibi-
tory signals [75]. It is believed that M141R (also called
vCD200 or vOX-2) sends inhibitory signals to CD200R+
DCs or macrophages, hereby decreasing the capacity of
antigen presenting cells to activate lymphocytes [76,77].
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This theory is supported by some in vivo data, where an
increased activation of circulating lymphocytes and
macrophages was observed when rabbits were infected
with a recombinant MYXV mutant lacking M141R [76].
Two other predicted MYXV proteins, M121R and
M122R, have been proposed to bind with MHC-1 on
the cell surface, since they have a similar gene
sequence as two natural ligands of MHC-I, namely the
natural killer cell group 2 (NKG2) in humans and the
lymphocyte 49 (LY-49) receptors in mice [1]. M128L
(vCD47) is another MYXV immunomodulator, encod-
ing a membrane-associated protein that resembles the
cellular immune CD47, also known as the integrin
associated protein (IAP) [1]. CD47 functions as a sti-
mulatory cell surface ligand for the signal regulatory
protein a (SIRPa) on the surface of myeloid cells [78].
CD47, together with SIRPa, form a cell-cell communi-
cation system mediating immune cellular functions
such as adhesion, mobility, activation and phagocytosis
of leukocytes [78,79]. The current hypothesis is that
M128L competes with CD47 for binding to SIRPa,
hereby disrupting the leukocyte cell functions
described above [80].
Pro-inflammatory caspases also play an important role
in the immune responses by regulating the activation
and secretion of various pro-inflammatory cytokines like
IL-1b and IL-18 [81]. These caspases are activated by a
multiprotein complex named the inflammasome [82].
M13L is a pyrin domain (PYD)-containing MYXV pro-
tein that binds with a pyrin-containing component
(called ASC) of the inflammasome, thereby inhibiting
the activation of IL-1b and IL-18 [81]. In addition,
M13L also directly inhibits cellular NF-B signaling by
binding NF-B1/p105 protein, which regulates the
secretion of pro-inflammatory cytokines such as TNF,
IL-6 and monocyte chemotactic protein (MCP)-1,
thereby giving M13L a dual immune-subversive role by
inhibiting both the inflammasome and NF-B signaling
[83]. Finally, M154R encodes a protein presenting 50%
identity with M2L, a vaccinia virus gene that was also
shown to inhibit induction of NF-B activation [45,84].
4.5. MYXV proteins with sequence similarity to HIV
proteins
Most genes of MYXV have orthologous family mem-
bers in other poxviruses, with the exception of M129R
and M130R. These two MYXV proteins exhibit a par-
tial sequence similarity with key proteins from another
highly immunomodulatory virus, namely human
immunodeficiency virus (HIV). The MYXV protein
M129R partly resembles the V3 loop of the HIV glyco-
protein 120 (gp120) (critical for HIV binding with
CCR5), but lacks a transmembrane domain and a sig-
nal sequence. The gp120 protein is involved in HIV
entry through binding with CD4 and CCR5 or CXCR4.
These receptors normally fulfill important roles in T-
lymphocyte effector functions [85]. It has been
hypothesized that M129R may fulfill a similar role as
gp120, namely mediating viral entry, but due to the
lack of a transmembrane domain, it is not clear yet if
M129R is expressed at all on the viral envelope of
MYXV [60]. The MYXV protein M130R is expressed
as a late protein and exhibits some sequence similarity
with the glutamine rich region of the HIV protein
transactivator (Tat) [60,86]. Tat is partially released
from HIV-infected cells, although other analyses also
revealed a nuclear location for this protein [87]. Many
different functions have been accredited to Tat, includ-
ing RNA binding, inhibition of T-cell proliferation,
induction of apoptosis in T-cells and neurons, inhibi-
tion of phagocytosis, decrease of apoptosis in infected
cells, interfering with NK-cells, etc. Because of the
large variety in functions of Tat, the MYXV protein
M130R needs to be tested for all these functions to
elucidate if M130R actually shares any functional rela-
tionship with HIV Tat [60,88].
4.6. MYXV proteins with unknown immune function
Finally, there are also still many MYXV proteins for
which no function or sequence similarity with other
obvious immunomodulatory counterpart proteins have
been found to date. The myxoma growth factor (MGF),
also designated M010L, is a secreted virulence factor
with similarity to transforming growth factor-alpha and
epidermal growth factor (including six conserved
cysteine residues involved in Epidermal growth factor
(EGF) receptor binding), which is necessary for a suc-
cessful infection in vivo, although the underlying
mechanism is still to be determined [89]. Because of a
strong sequence similarity with the VACV protein B19R
from strain Copenhagen (called B18R in the VACV
strain Western Reserve), it was originally thought that
M135R was a viral scavenger of type-1 IFN, thereby
inhibiting this ligand family [60,90-92]. However, this
hypothesis has not been validated since all binding and
inhibition assays conducted to date, designed to demon-
strate that M135R can indeed interact with type-1 IFN,
were negative [90]. Nevertheless, M135R remains an
important virulence factor for myxomatosis, so more
research on the exact function of this protein is
warranted.
Finally, the MYXV protein M144R shows similarity to
the VACV proteins C3L (31% by means of blast search)
and B5R (37% by means of alignment analysis) [1,60].
These latter proteins have a complement-binding and
structural function respectively, making it tempting to
speculate that M144R also possesses these functions,
although this still needs to be confirmed [60].
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5. Vaccination strategies against myxomatosis
5.1. Current MYXV vaccines
Prevention of myxomatosis is a matter of great impor-
tance for industrial/domestic rabbit farms for laboratory
and pet rabbits because of its high prevalence and mor-
tality rate [10]. This prevention can be partly achieved
through controlling vectors such as mosquitoes and
fleas. However, such sanitary measures are rarely suffi-
cient and therefore, an effective vaccination strategy is
desired for successful protection against MYXV [93].
Since a robust cellular immunity is necessary for protec-
tion against MYXV, inactivated vaccines have generally
proven unsuccessful [93]. Plasmid-based subunit vac-
cines were also unable to protect rabbits from disease,
even though both antigen-specific cell-mediated and
humoral immune responses were induced [94]. There-
fore, only live vaccines, which can be divided into two
groups, are commercially available to date. The first
group of vaccines consists of heterologous vaccines
based on the closely related but nonpathogenic lepori-
poxvirus Shope fibroma virus (SFV), due to the close
antigenic resemblance of this virus with MYXV [93].
SFV originates from the Eastern cottontail rabbit (Sylvi-
lagus floridanus) and provides considerable cross-pro-
tection against MYXV without causing disease in
European rabbits older than two weeks [2,10]. Possible
reasons for this attenuated phenotype of SFV might lie
in the partial or complete deletion of several SFV genes
found in MYXV, such as those encoding predicted (eg
M150R, M139R) or confirmed (eg Serp-1, M135R) viru-
lence factors [95]. Current commercial SFV vaccines are
based on the original Shope OA strain, Boerlage strain
or closely related strains [93]. The main disadvantage of
these vaccines is that they only induce a limited amount
of protective immunity that lasts no longer than three
months [96,97]. Contradictory findings have been
reported as to whether SFV-based vaccines can comple-
tely prevent clinical signs of myxomatosis upon infection
[98,99]. A possible explanation in this regard could be
differences in the adjuvant used or the dosage of vaccine
virus used [98]. In addition to adjuvant and dosage of
the vaccine virus used, also the vaccination schemes
(route, number of injections) could influence the level of
protection [99] The second group of vaccines consists of
homologous attenuated live vaccines, such as the SG33,
Borghi or BTK/RB/84 strains of MYXV [93,100]. SG33
is a homologous vaccine strain, derived from the Lau-
sanne strain of MYXV by serial passages on RK13 rabbit
kidney and chicken embryo cells at 33°C [101], during
which genomic deletions were introduced [15]. Specifi-
cally, a large deletion near the right end of the genome
was seen during preliminary analysis [102]. This was
later confirmed when the SG33 genome was analyzed
[15,45]. These deletions include the loss of important
immunomodulatory genes, such as Serp-2, M148R,
M149R, M150R, M152R, M153R, M154R and M-T1
[15,45]. In addition, a mutation of the M143 gene was
reported in the SG33 strain [15]. The recent analysis of
the entire SG33 genome also gave new information con-
cerning the origin of this vaccine strain. It was estab-
lished that its present sequence composition is the
result of field recombination between a wild-type Lau-
sanne strain and a Californian MSD-derived vaccine
strain [45]. The Borghi strain is a homologous vaccine
strain, derived from the Californian strain MSD of
MYXV by serial passages in RK13 cells. The attenuation
of the Borghi strain could be due to truncation of Serp-
2, M-T4 and/or a mutation in the M121 gene [15].
These homologous MYXV-based vaccines induce a
stronger protective immune response than any of the
current SFV vaccines and they induce disease protection
at least four months after vaccination [93]. The main
disadvantage of these vaccines, however, is a reported
immunodepression in young rabbits after vaccination.
Still, no problems were reported after vaccination with
SG33 of young Angora rabbits, which is a breed known
to be particularly sensitive to the myxomatosis virus
under field conditions [103]. Other side effects
reported include lesions of the skin, edema and rash at
the injection point, as well as secondary myxoma
lesions after vaccination with SG33 [103]. Recently,
vaccination with an Uriarra strain deficient for M063R
was also evaluated giving long-term results similar to
those of heterologous live vaccines [104]. More potent
vaccine candidates have been constructed through
deletion of one or more virulence genes (e.g. M-T7 or
M007L/R, M010L and M011L) in the naturally attenu-
ated MYXV Ur strain [7,12,105]. Vaccination with
these vaccines, however, is accompanied by mild clini-
cal symptoms in adult rabbits, thereby making them
still too virulent for widespread use as a vaccine. When
all three deletions were created simultaneously in the
same vaccine, no symptoms were observed in test rab-
bits but the long-term protection against wild-type
MYXV was also limited [7,12,105]. By inserting a VP60
(rabbit hemorrhagic disease (RHD) capsid component
that induces a protective antibody response against
RHD [106]) construct in the SG33 strain, another
potent vaccine strain was created which protected rab-
bits against both MYXV and RHD [107]. Despite show-
ing promising preliminary results, this recombinant
vaccine is still not commercially available [93].
In general, the currently recommended vaccination
scheme against myxomatosis consists of a primary vacci-
nation with SFV at three or four weeks of age and a
booster vaccination with a homologous MYXV-based
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vaccine three weeks to two months later, depending if
the rabbits are exposed to a high or low infection risk.
The rabbits then need to be re-vaccinated every four to
six months, depending on the infection risk [93].
5.2. Vaccination campaigns to protect European rabbits in
the wild
The European rabbit is also an important part of Eur-
ope’s ecosystems and it is an essential source of food
for at least 29 predatory species [108]. MYXV, together
with RHD and hunting, is an important reason for the
poor condition of some of these indigenous prey popu-
lations, such as the Iberian lynx and many raptors
[109]. Management strategies such as captivity breed-
ing, restocking, translocations, predator control or
habitat management, aimed at raising the number of
rabbits for hunting and conservation purposes, have
been attempted but they have had very little impact on
the overall rabbit population numbers, especially in
Mediterranean ecosystems [110]. Therefore, manage-
ment strategies should include a vaccination program,
with adequate procedures [97,110]. However, all of the
currently available commercial vaccines are not suita-
ble for vaccination in the wild since they have to be
administered individually [93,111]. Therefore, attempts
have been made to develop transmissible vaccines that
are able to serially spread throughout the rabbit popu-
lations in the wild. For this reason, twenty MYXV field
strains were isolated from the wild and were evaluated
for their virulence and horizontal transmissibility [112].
One of these field strains, isolate 6918, showed appro-
priate characteristics for safety and immunization,
which also remained the case after inserting a VP60
construct for inducing additional immunization against
RHD [112-114]. The attenuated phenotype of isolate
6918, in comparison to the Lausanne MYXV strain
from which it originated, is possibly caused by frame-
shift mutations that severely disrupted at least four dif-
ferent viral genes (M009L, M036L, M135R, M148R)
[115]. The disruption of M135R and M148R could be
important since they are known virulence factors
[49,90,115]. The use of such a vaccine, with a
successful horizontal transmission capacity, could
eventually lead to the protection of a sufficient portion
of the rabbit population after capturing, directly vacci-
nating and releasing a small number of rabbits [112].
Therefore, a field test was authorized on a small island
near mainland Europe with a dense rabbit population.
After inoculating one fourth of the population, a lim-
ited transmission was seen with a seroconversion in
50% of the non-inoculated rabbits [116]. Although pro-
mising, the relatively low transmissibility might be an
obstacle for immunization in less densely populated
areas, so more field tests are needed to fully investigate
the potential of this vaccine [117].
Apart from the vaccination itself, the time of vaccina-
tion has to be taken into account also in order to maxi-
mize the vaccination campaign’s effectiveness in areas
where myxomatosis is already enzootic. The time of vac-
cination would be most efficient before the start of the
yearly epidemics, since the herd immunity will then be
at its lowest and numerous non-immune kits will have
been born [117]. Research has shown that there is a
two-month window between the birth of susceptible
animals and the appearance of a myxomatosis epidemic,
which would be the best time for introducing a new
MYXV strain in an already endemic area [118]. This,
however, could be difficult to implement since the tim-
ing of the epidemics varies yearly [117].
6. Applications of myxoma virus for human
medicine
6.1. MYXV proteins as therapeutics for allograft
vasculopathy and atherosclerosis (Table 3)
Transplant vasculopathy is a pathological syndrome that
is associated with chronic rejection of organ transplants
and it is the leading cause of transplanted organ loss
after the first year post-transplant [119]. Its histopathol-
ogy is characterized by narrowing of the vascular lumen
as a result of proliferation of smooth muscle cells and
fibroblasts. Furthermore, material of the extracellular
matrix is deposited and activated leukocytes infiltrate
the vessel wall. There is also a large histopathological
resemblance between graft vasculopathy and non-
Table 3 Clinically adapted MYXV proteins for treating inflammatory diseases
Gene
product
Potential clinical use References
Serp-1 Secreted serpin that effectively inhibits vascular inflammatory responses and has been tested in human clinical trials to
treat acute coronary syndrome.
[122-125]
Serp-2 Viral anti-apoptotic serpin effective in animal models but not yet tested in humans. [19]
M-T1 Chemokine inhibitor that reduces the allograft rejection and stabilizes plaque formation during artherosclerosis. [127-129]
M-T7 Chemokine inhibitor that attenuates systemic inflammatory responses and inhibits leukocyte infiltration, thus preventing
transplant rejection.
[126-129]
M-T2 TNF/TNFR inhibitor but not yet tested as a potential therapeutic. [28,30,129]
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transplant forms of atherosclerosis, due to overlapping
pathogenetic pathways [120]. Atherosclerosis can be
caused by many factors, including hyperlipidemia, dia-
betes and hypertension [121]. Numerous proteases are
important factors for the development of atherosclerosis,
since they help regulate atherosclerosis-related vascular
remodeling. An important group of these proteases are
the serine proteases since they not only mediate matrix
breakdown, but also activate and release diverse pro-
inflammatory cytokines and growth factors, thus activat-
ing a wide spectrum of leukocyte receptors and promot-
ing increased leukocyte migration into damaged tissues
[122]. The ability of purified recombinant Serp-1 protein
to inhibit several of these serine protease in a species-
independent manner raises the possibility that this viral
protein could attenuate the vascular inflammatory
responses in a wide variety of cardiovascular diseases,
such as atherosclerosis, transplantation rejection and
injury vasculopathy [122,123]. Indeed, there are poten-
tially numerous applications in human medicine, for
example treating other diseases driven by systemic
inflammation. Recently, successful human Phase II clini-
cal trials have been reported using purified Serp-1 pro-
tein to treat patients with acute coronary syndromes
[124,125].
The MYXV protein Serp-2, on the other hand, is an
intracellular regulator that selectively binds and inhibits
mediators of T-cell killing, enabling a generalized reduc-
tion of arterial inflammation through a granzyme B/per-
forin dependent pathway. This may prolong certain
specific T-cell functions, allowing subsets of T-cells to
provide anti-inflammatory actions or alternatively it may
initiate apoptotic responses in disease-causing macro-
phages and/or smooth muscle cells [122]. Serp-2 protein
has not yet been tested in clinical trials [19].
Another important feature of vascular inflammation is
the attraction of leukocytes by chemokines to specific
sites in the vasculature and their migration through sur-
rounding tissues [121]. The M-T1 and M-T7 secreted
proteins of MYXV, which inhibit in a species-indepen-
dent fashion a variety of diverse chemokines, block the
chemotaxis of leukocytes into these sites of inflamma-
tion, subsequently reducing the allograft rejection in a
murine aortic allograft model [126-129]. In the case of
immune-based joint diseases like rheumatoid arthritis,
high quantities of pro-inflammatory cytokines, such as
TNF, are found in the synovial fluids and the amount of
TNF elevation closely correlates with disease severity.
Subsequently, TNF is considered an important target for
treatment [129]. The MYXV protein M-T2 has high affi-
nity for rabbit TNF, and also can bind and inhibit
human TNF-receptors, but more research is still needed
to determine if this MYXV protein would have thera-
peutic potential [28-30,129].
6.2. Applications for MYXV as a live oncolytic virus to
treat cancer
MYXV is also considered a promising oncolytic virus
that is essentially harmless to non-lagomorphs, including
mice and humans, but nevertheless is able to selectively
infect and kill many diverse human tumor cells. This
translational application of MYXV is based on the
genetic alterations in intracellular signaling pathways
commonly found in cancer cells, which allows the trans-
formed cells to continue dividing without being con-
trolled by normal cellular checkpoints [20,130-136]. On
the other hand, these cellular checkpoints also form an
important part of the innate self-protection mechanisms
against viral infection, and therefore, most transformed
cells tend to be more susceptible to many viral infec-
tions [134].
The absence of such viral protection mechanisms in
cancer cells makes the selective replication possible for
at least some oncolytic viruses that normally cannot
propagate successfully in human tissues, such as MYXV
[134]. More specifically for MYXV, malignant cancer
cells in general lose the ability to induce the TNF/IFN-b
synergistic anti-viral state, a feature that largely deter-
mines the host range of MYXV in primary human cells
[130]. In addition, the host range of MYXV in human
cancer cells is also influenced by oncogenic activation
and tumor suppressor dysfunction [137]. Indeed, MYXV
has been shown to be capable of infecting a wide variety
of human cancer cell lines in vitro and it has been pro-
ven to be a safe and potent oncolytic virus in vivo
[132,138,139]. However, in order to be suitable for anti-
tumoral therapy in the clinic, MYXV also needs to
cause regression of metastatic tumors in immune com-
petent patients [132]. When administered systemically,
MYXV was able to decrease murine B16 melanoma
lung metastasis in an immune competent mouse model.
This regression of tumors was significantly enhanced by
the chemotherapeutic rapamycin [140], an effect which
was later on shown to be achieved by reconfiguring the
internal cell signaling environment of many cancer cells
to one which is more optimal for productive virus repli-
cation [134]. A more elaborate description of MYXV as
an oncolytic virus has recently been reviewed by Liu et
al. [19], and the particular exploitation of MYXV to
purge cancer cells from human bone marrow trans-
plants is described by Rahman et al. [141].
7. Discussion and conclusions
Research on MYXV has been conducted for many years
and the interest in this virus is basically two-fold. On the
one hand, MYXV is an important pathogen for the Eur-
opean rabbit population and due to economical reasons
and ecological consequences, MYXV merits attention for
both population control strategies in places (like
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Australia) where feral rabbit populations have become
damaging, as well as vaccination strategies for situations
(like commercial rabbit breading operations, or for native
rabbits in Europe) where myxomatosis is a detrimental
disease. On the other hand, MYXV is also gaining more
interest from a therapeutic point of view now that it has
been shown to have great potential for treatment of cer-
tain inflammatory-based diseases and cancer in humans.
Thus, it is of utmost importance to continue to acquire
detailed knowledge on the behavior and pathogenesis of
this rabbit-specific viral pathogen in both permissive (ie
rabbit) and nonpermissive (especially human) hosts.
It has become clear over the years that developing
effective vaccines and efficient vaccination strategies for
rabbits are not as straightforward as originally thought.
The major problems encountered are balancing the
need to induce a potent acquired immune response
without being accompanied by disease symptoms. Dele-
tions of MYXV virulence genes, but maintaining virus
replication fitness, is probably the best approach for a
longer lasting immunity, as has been shown by Adams
et al. [105]. However, improved potency in terms of the
desired immune response was often accompanied by the
appearance of some clinical symptoms in vaccinated
rabbits, indicating that the level of protection that can
be achieved to date with the available vaccines on the
market might remain the best approach since these vac-
cines are of no risk for the rabbit itself.
Another possibility for creating a more potent immune
reaction against MYXV could be insertion of important
immunogenic genes of MYXV into heterologous vaccine
platforms. Such approach has already been reported for
canine influenza, equine influenza virus, West Nile virus
and bovine viral diarrhea virus, where virulence genes of
these viruses were inserted into an equine herpesvirus
type 1 (EHV1) vaccine [142-145]. The rationale behind
the insertion of MYXV immunogenic genes into an
equine pathogen is based on the fact that EHV1 grows
extremely well in rabbit cells and hence, rabbit kidney
(RK13) are the most commonly used in vitro cell line to
grow EHV1 [146,147]. Still, despite this efficient growth
in vitro, it needs to be determined whether EHV1 is cap-
able of inducing robust immune responses in rabbits in
vivo. Preliminary experiments, however, have shown that
rabbits are susceptible for EHV1 infection (Van de Walle
et al., unpublished results), indicating that a recombinant
EHV1 vector expressing MYXV proteins could prove a
novel strategy to efficiently protect rabbits against
MYXV. In addition, another possible viral vector vehicle
for immunization against MYXV could be exploited with
nonpathogenic variants of Vesicular Stomatitis Virus
(VSV) since it has shown excellent replication kinetics in
the rabbit during experiments for vaccine development
[148-150].
Numerous discoveries have been made concerning the
immunomodulatory capabilities of MYXV since the
sequencing of the full MYXV genome, although the
functions of many candidate proteins remain undeter-
mined to date. For some of the latter class of proteins, a
putative function had been sometimes ascribed based on
sequence similarity with other immunomodulatory viral
or cellular proteins, but these conjectures have not
always been validated, such as the cases of M063 [1,62]
and M135 [90]. This indicates that one needs to be judi-
cious when predicting how a viral protein functions
solely based on sequence or structural similarities.
Rather, a true biological role can only be assigned after
thorough in vitro and in vivo experimentations.
In terms of clinical applications, several of the MYXV
immunomodulatory proteins have become promising can-
didates for treatment of inflammation-based disorders. To
date, the first of these virus-derived drugs (Serp-1) has
behaved particularly well in humans, with essentially no
clinical adverse side effects, in Phase I and II clinical trials.
MYXV as an oncolytic virus candidate also shows consid-
erable potential, both against murine cancers in immuno-
competent mouse hosts, as well as human cancers
xenografted into immunodeficient mice. MYXV appears
to be capable of substantially counteracting malignancies
derived from many tissues, especially in combination with
rapamycin, and the live virus has exhibited essentially no
detectable side effects in all murine hosts tested, even
mice that are extensively immunocompromised. In the
future, insertion of selective anti-cancer therapeutic genes
[131] and/or deletion of MYXV virulence genes [151]
could further augment its safety against all vertebrate
hosts (including rabbits) and therefore improve its clinical
suitability. For example, the Interleukin-15 (IL-15) gene
has been inserted into the MYXV genome and this recom-
binant virus remained capable of replicating in vitro to a
degree resembling wild MYXV [131]. Very promising
results, concerning safety improvement, have also been
obtained by deleting the host range genes M063 or M135
since either deletion showed significant attenuation in its
natural rabbit host while retaining and even improving the
viral oncolytic capabilities compared to wild MYXV [151].
The exploitation of MYXV constructs that are nonpatho-
genic in all known vertebrate hosts, but still potently onco-
lytic against human cancers, will hopefully make MYXV
an important factor in improving the outcome of treat-
ment for numerous cancers in the future [19].
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